Abstract
Non-psychotropic cannabinoids, as well as psychotropic cannabinoids, extracts of Cannabis sativa L. and derived products containing cannabinoids have gained the status of novel foods within the European Union/EU, starting January 2019, thus requiring authorization for the placing on the EU market. With this status comes also the consolidation of an emerging market. At the same time, it should be noted that cannabinoids have already been the object of research, study and applications, for at least decades of modern science, showing comprehensive and extraordinary properties for use as therapeutic agents. The purpose of present paper is to provide an overview of the main non-psychotropic cannabinoids and their pharmacological profiles, with the aim of advocating further research into their potential for various applications, mainly as therapeutic agents, and most importantly with the aim of advocating for pursuing the innovation process all the way to the market uptake of related innovative products.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of the Academy of Romanian Scientists Series on Physics and Chemistry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
